| Name | (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide |
|---|---|
| Synonyms |
Lemborexant API
Lemborexan (1S,2R)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-1-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecboxamide E-2006; E 2006; E2006; LEMBOREXANT; DAYVIGO Lemborexant //BP Cyclopropanecboxamide, 2-[[(2,4-dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)-, (1R,2S) (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide labradon Lemborexant Impurity 1 (1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecboxamide (1R,2S)-2-[(2,4-DIMETHYLPYRIMIDIN-5-YL)OXYMETHYL]-2-(3-FLUOROPHENYL)-N-(5-FLUOROPYRIDIN-2-YL)CYCLOPROPANE-1-CBOXAMIDE lemborexant,E2006 Dayvigo (1R,2S)-2-[[(2,4-dimethyl-5-pyrimidine)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridyl)cyclopropaneformamide (Leborethen) E-2006 Lemborexant Lemborexant (1R,2S)-2-{[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide lemborexant / E-2006, CID 2-((1S,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)cyclopropyl)-N-(5-fluoropyridin-2-yl)acetamide |
| Description | Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia. |
|---|---|
| Related Catalog |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 596.1±50.0 °C at 760 mmHg |
| Molecular Formula | C22H20F2N4O2 |
| Molecular Weight | 410.417 |
| Flash Point | 314.3±30.1 °C |
| Exact Mass | 410.155426 |
| PSA | 77.00000 |
| LogP | 3.16 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.619 |
| Storage condition | 2-8℃ |